NCT05663593已完成1 期
A Randomised, Double-blind, Placebo-controlled, 2-part Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Oral Doses of HSK31858 in Healthy Volunteers
Haisco Pharmaceutical Group Co., Ltd.1 个研究点 分布在 1 个国家目标入组 74 人开始时间: 2022年2月23日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 74
- 试验地点
- 1
- 主要终点
- The number and severity of treatment emergent adverse events (TEAEs)
研究概览
简要总结
This is a phase I, randomised, double-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of HSK31858 in healthy volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Must have given written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
- •Adult males and females, 18 to 45 years of age (inclusive) at Screening.
- •Body mass index ≥ 18.0 and ≤ 28.0 kg/m2, with a body weight ≥ 45 kg at Screening.
- •Be nonsmokers (including tobacco, e-cigarettes, and marijuana) for at least 1 month prior to first study drug administration.
- •Medically healthy without clinically significant abnormalities at Screening and predose on Day
- •Conventional 12-lead ECG recording in triplicate (the mean of triplicate measurements will be used to determine eligibility at Screening and predose on Day 1) consistent with normal cardiac conduction and function.
排除标准
- •History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or surgery within the past 3 months determined by the PI to be clinically relevant.
- •Subjects has increased risk of infection:
- •History and/or presence of tuberculosis (TB).
- •Body temperature of > 37.7℃.
- •Blood neutrophil count <1.5 × 109/L, or white blood cell count <3.5×109/L (Screening and Day -1).
- •Is in high risk-group (i.e., men who have had unprotected sex with men, women who have had sex without a condom with men who have sex with men, people who have had sex without a condom with a person who has lived or travelled in Africa, people who inject drugs, people who have had sex without a condom with somebody who has injected drugs, people who have caught another sexually transmitted infection, people who have received a blood transfusion while in Africa, eastern Europe, the countries of the former Soviet Union, Asia or central and southern America) for human immunodeficiency virus (HIV) infection within the last 6 months.
- •Other latent or chronic infections (e.g., recurrent sinusitis, genital or ocular herpes, urinary tract infection) or at risk of infection (surgery, trauma, or significant infection) within 3 months of Screening, or history of skin abscesses within 3 months of Screening.
- •Clinically significant lower respiratory tract infection not resolved within 4weeks prior to Screening, as determined by the PI.
- •Volunteers with active malignancy or neoplastic disease in the previous 5 years other than superficial basal cell carcinoma.
- •Disease history suggesting abnormal immune function or use of or plans to use systemic immunosuppressive (e.g., corticosteroids, methotrexate, azathioprine, cyclosporine) or immunomodulating medications (e.g., interferon) during the study or within 4 months prior to the first study drug administration.
- •Some subjects lacking functional Dipeptidyl peptidase 1 (DPP1) enzyme have been described to have periodontitis and palmoplantar hyperkeratosis:
- •Subjects with signs of current gingivitis/periodontitis. Gingival evaluation (by inspection) will be performed by a dental hygienist or trained study physician.
- •Subjects with a history of hyperkeratosis or erythema in palms or soles.
- •Liver function test results (i.e., aspartate aminotransferase [AST], alanine aminotransferase [ALT], and gamma glutamyl transferase [GGT]) and total bilirubin elevated more than 1.5 fold above the ULN.
- •Hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), syphilis antibody and human immunodeficiency virus (HIV) antibody test are positive at screening.
- •Presence or having sequelae of gastrointestinal, liver, kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
- •History of alcohol abuse within 12 months prior to first study drug administration or positive alcohol breath test. Regular alcohol consumption defined as > 21 alcohol units per week (where 1 unit = 284 mL of beer, 25 mL of 40% spirit or a 125 mL glass of wine).
- •Use of any prescription or over-the-counter medication (including herbal products, diet aids, and hormone supplements) within 14 days or 5 half-lives of the medication (whichever is longer) prior to the first study drug administration, except occasional use of paracetamol. Use of any IP or investigational medical device within 30 days prior to Screening, or 5 half-lives of the product (whichever is the longest).
- •Donation of blood or plasma within 30 days prior to first study drug administration, or loss of whole blood of more than 500 mL within 30 days prior to randomization, or receipt of a blood transfusion within 1 year of first study drug administration.
- •Participation in another investigational clinical trial within 60 days prior to the first study drug administration.
- •Pregnant or lactating at Screening or planning to become pregnant (self or partner) at any time during the study, including the Follow-up period.
研究组 & 干预措施
HSK31858
Experimental
Single or multiple oral doses of HSK31858 Tablet, orally once daily
干预措施: HSK31858, tablet (Drug)
Placebo
Placebo Comparator
Matching placebo Tablet, orally once daily
干预措施: Placebo, tablet (Drug)
结局指标
主要结局
The number and severity of treatment emergent adverse events (TEAEs)
时间窗: 56 days after multiple dose
To assess the safety and tolerability of multiple oral dose of HSK31858 in healthy volunteers
次要结局
- Cmax(within 30 minutes before administration until 72 hours after administration)
- Tmax(within 30 minutes before administration until 72 hours after administration)
- AUC0-last(within 30 minutes before administration until until 72 hours after administration)
- t½(within 30 minutes before administration until 72 hours after administration)
- Absolute neutrophil count (ANC) normalized relative neutrophil elastase (NE) Activity(within 30 minutes before administration until until 56 days after administration)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus AureusInfections, BacterialNCT00539994GlaxoSmithKline57
已完成
1 期
A Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of StaphylococcusNasal Decolonization of Staphylococcus AureusNCT04767321Pharma Holdings AS15
已完成
1 期
SG301-SC Injection Safety Study in Subjects With Systemic Lupus ErythematosusSystemic Lupus Erythematosus (SLE)NCT06144710Hangzhou Sumgen Biotech Co., Ltd.48
已完成
2 期
To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 ParticipantsCovid19NCT04914377Novatek Pharmaceuticals55
已完成
1 期
A Study To Evaluate the Safety of XW001 Inhalation in Children With RSVRSV InfectionNCT05779995Hangzhou Sciwind Biosciences Co., Ltd.61